June 3, 2024 Average drug sales 0 Comments Time is money in drug development – Healthcare Economist Delays in drug approvals cost pharmaceutical firms money. These costs include both lost sales as well as additional cost if clinical trials need to ... Read More
April 16, 2024 Biosimilars 0 Comments Biosimilar Market Report – Healthcare Economist Samsung Bioepis has a Biosimilar Market Report for Q2 2024. Some key highlights: As of April 2024, the FDA ... Read More